By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, ...

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Hims & Hers (HIMS 1.39%) is in the middle of a very public dispute with Novo Nordisk (NVO 1.43%). However, this fight isn't ...

A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age ...

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

Hims & Hers Health said in a 10-K filing that it received a letter from the staff of the Securities and Exchange Commission’s ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Shares of Hims & Hers Health (NYSE:HIMS) are trading lower this morning after yesterday’s earnings, and the reason is ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock ...

Consumer health and wellness platform Hims & Hers will ramp up its international presence with the acquisition of Australian digital health company Eucalyptus, it announced Thursday.  | Purchasing the ...

The telehealth platform logged a quarterly profit of $20.6 million as it worked to offer a wider range of treatments and grew ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.